In contrast, Lu et al., 2019 [127], in 149 breast cancer patients, showed significantly increased levels of BNP in patients with cardiotoxicity during anthracycline treatment compared to the non-cardiotoxicity group and it was an independent predictor of anthracycline-related cardiac dysfunction (p = 0.047). This evidence concerns the gene NPPB and breast carcinoma.